Quantcast

Syngene Introduces U:Genius3 – A Complete Gel Doc System for Quick and Simple Gel Imaging

January 30, 2012

Syngene, a world-leading manufacturer of image analysis solutions today introduced its U:Genius3, complete budget gel imaging system.

Frederick, MD (PRWEB) January 30, 2012

Syngene, a world-leading manufacturer of image analysis solutions today introduced its U:Genius3, complete budget gel imaging system. This compact system with its button driven key pad is simple to set up, making it ideal for busy laboratories that need rapid and accurate gel imaging.

The U:Genius3 comes with a sensitive 3 million pixel CCD camera inside a compact darkroom. The cost-effective system includes overhead Epi white light and is versatile, offering multiple illumination options to allow high-resolution imaging of 1D DNA and protein gels stained with a range of dyes.

The U:Genius3 features a built in processor and simple to use intuitive “button controlled” integral key pad so can be used straight from the box. The system can be fitted with the new Ultra-Slim LED Blue Light Transilluminator in laboratories where safety and UV sample damage are issues. The transilluminator slides out of the darkroom to aid viewing and band cutting, and there is also a white light converter screen option available for scientists wanting to view protein gels, thus maximizing the use of vital laboratory space.

Laura Sullivan, Syngene´s Divisional Manager explained: “Many researchers in busy laboratories often just want a quick, accurate image of their gels, so they need an inexpensive press button system which takes seconds to set up.”

Laura added: “We have listened to those requests and the result is the U:Genius3. We´re confident that scientists who try the U:Genius3 will agree the system is ideal where budget and space are limited, but doesn´t compromise on generating superb results with outstanding resolution, making U:Genius3 the most cost-effective gel doc currently available.”

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/1/prweb9137091.htm


Source: prweb



comments powered by Disqus